Applied Research Systems Ars Holding N.v.

Exiris S.r.l.

Mauro Biffoni

Armin Lahm

Ruben Papoian

Gessica Filocamo

Lucia Ricci-Vitiani

Chantal Paolini

Hans-Friedrich Grunert

Mirko Brunetti

Paola Gallinari

John Thompson

The present disclosure relates to monoclonal antibodies anti-FGFR4 and their use as medicaments and diagnostic agents. In particular, it relates to an antibody which specifically binds to the acid box domain of FGFR4 and to specific portions thereof. Nucleic acids coding for said antibody, vectors and host cells for their expression and production, antibody-drug conjugates and pharmaceutical compositions comprising said antibody are also within the scope of the present disclosure. The present disclosure also relates to antibodies anti-FGFR4 for use for detecting, killing, affecting or inhibiting development and/or differentiation of colon cancer stem cells.

Monoclonal antibody anti-FGFR4

A method to prevent graft rejection of transplanted cells, tissues or organs without general immunosuppression is described. The method employs a newly discovered protein, LAG-3. When allogeneic or xenogeneic cells are engineered to express LAG-3 on their surface and transplanted, immune destruction of the implanted cell, tissue or organ is prevented, while the host's immune system remains functional. A particular application of this method allows the preparation of a universal gene therapy host cell expressing LAG-3 on its surface for protection from graft rejection by a host's immune system.

Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (LAG-3)

Growing community of inventors

Rome, Italy

Mauro Biffoni